BMS-833923

CAT: 0804-HY-13809-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13809-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BMS-833923 (XL-139) is an orally biocompatible Smoothened (Smo) inhibitor with anti-tumor activity. It can inhibit the binding of BODIPY cyclopamine to SMO in a dose-dependent manner with an IC50 of 21 nM[1].
CAS Number
[1059734-66-5]
Product Name Alternative
XL-139
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Smo
Type
Reference compound
Related Pathways
Apoptosis; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bms-833923.html
Concentration
10mM
Purity
99.82
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2
Molecular Formula
C30H27N5O
Molecular Weight
473.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Steven B, et al. Abstract B192: Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Molecular Cancer Therapeutics: December 2009; Volume 8, Issue 12, Supplement 1.|[2]Du J, et al. Disruption of SHH signaling cascade by SBE attenuates lung cancer progression and sensitizes DDP treatment. Sci Rep. 2017 May 15;7 (1) :1899. |[3]AlMuraikhi N, et al. Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells. Stem Cells Int. 2019 Nov 21;2019:3435901. |[4]Gu D, et al. Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers (Basel) . 2018 Oct 26;10 (11) :403. |[5]Riedlinger D, et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014 Aug;21 (8) :607-15.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products